Will Bayer Corporation Buy Onyx Pharmaceuticals, Inc.?

February 16, 2007 -- The good news keeps coming for Onyx Pharma, which certainly deserves the trophy for Most Improved in biotech this week. Yesterday, after the closing bell, Onyx announced its Q4 and full-year 2006 financials, showing that its losses are being reduced because of better than expected revenues from cancer drug Nexavar. Given the recent good news about Nexavar as a treatment for liver cancer, we look at revenue estimates for the drug and estimate what Bayer might pay to acquire Onyx and the half of Nexavar it does not already own...